| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10594531 | Bioorganic & Medicinal Chemistry Letters | 2012 | 6 Pages |
Abstract
AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Patrick Raboisson, Anna Breitholtz-Emanuelsson, Henrik Dahllöf, Louise Edwards, William L. Heaton, Methvin Isaac, Keith Jarvie, Annika Kers, Alexander B.E. Minidis, Anna Nordmark, Susan M. Sheehan, Abdelmalik Slassi, Peter Ström, Ylva Terelius,